Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Gaush Meditech Ltd. ( (HK:2407) ) is now available.
Gaush Meditech Ltd has called its annual general meeting for May 28, 2026, in Beijing, where shareholders will vote on routine corporate matters including the adoption of the 2025 audited financial statements and the re-election of three executive directors. Investors will also decide on the re-appointment of Ernst & Young as auditor, with remuneration set in a defined range, and on granting the board a general mandate to issue additional shares, which could provide funding flexibility but may have dilution implications for existing shareholders.
The proposed share issuance mandate, which excludes standard rights issues, employee option plans and scrip dividends, would allow directors to allot new shares and related securities during a specified period in line with Hong Kong listing rules. If approved, these resolutions will reinforce continuity in Gaush Meditech’s leadership and audit oversight while equipping the company with expanded capital-raising tools as it navigates future growth opportunities and competitive pressures in the meditech sector.
More about Gaush Meditech Ltd.
Gaush Meditech Ltd is a Cayman Islands-incorporated company listed in Hong Kong that operates in the medical technology sector. The company focuses on developing and supplying healthcare and meditech solutions, targeting hospitals and clinical users in mainland China and broader Asian markets.
Average Trading Volume: 63,603
Technical Sentiment Signal: Sell
Current Market Cap: HK$760.1M
For an in-depth examination of 2407 stock, go to TipRanks’ Overview page.